Shanghai Fosun Pharma received approval for a Hong Kong IPO that will raise between $600 million and $800 million; China Cord Blood Group announced Kohlberg Kravis Roberts will invest $65 million into the company; China Cord Blood also said it will build a $32 million stem cell biomedical engineering facility in Chongqing; Lee's Pharma in-licensed the China rights to a gastrointestinal-protective form of aspirin from PLx Pharma; Hainan Haiyao will spend $3.2 million to develop a cephalosporin antibiotic intermediate with Shanghai Knowshine; Lotus Pharmaceuticals' new Beijing headquarters has drained the company of cash, which may cause its delisting; and ThermoGenesis received SFDA approval for its BioArchive system, a device used for cryopreserving and archiving blood stem cells from umbilical cords. More details.... Stock Symbols: (SHA: 600196) (NYSE: CO) (HK: 950) (SHE: 000566) (OTCBB: LTUS) (NSDQ: KOOL) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});